By Using "CAR T-cell" technology, UAE begins its trial of locally producing immune cell therapy

The Abu Dhabi Stem Cell Center has started the first trial of its kind in the United Arab Emirates to study the efficacy and safety of immune cell therapy using CAR T-cell receptors in the treatment of blood cancers.

Immune cell therapy with targeted CAR T-cell receptors is one of the new technologies globally recognized for immunotherapies, which use the body's defense system by reprogramming immune cells, which are an essential component of the body's anti-tumor response mechanism, preparing them to perform through research tasks For cancer and its elimination, these programmed cells become a living drug that travels through the body and constantly uses the immune system to attack disease.

The Director of the Bone Marrow Transplant Program in Abu Dhabi, and the principal investigator involved in the immune cell trial, Dr. Fatima Al Kaabi, expressed her pride in this first achievement of its kind in the UAE and the region.